Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
Steven E. Schild,Shauna L. Hillman,Angelina D. Tan,Helen Ross,William L. McGinnis,Yolanda A. Garces,David Graham,Alex A. Adjei,James R. Jett +8 more
TLDR
The median survival of the stage III patients was quite favorable, and it is believed that this may have been due to a robust central review program of radiotherapy plans before treatment, ensuring compliance with protocol guidelines along with very low exposure of the heart to radiotherapy.About:
This article is published in Journal of Thoracic Oncology.The article was published on 2017-04-01 and is currently open access. It has received 14 citations till now. The article focuses on the topics: Radiation therapy & Chemoradiotherapy.read more
Citations
More filters
Journal ArticleDOI
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
TL;DR: The history and evolution ofCAR-T is described, the structure and preparation of CAR-T are generalized, the latest advances on CAR-Ts in different tumor types are summarized, and the current challenges and prospects are presented to provide guidance for subsequent research.
Journal ArticleDOI
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer.
Yosef Landman,Oded Jacobi,Noga Kurman,Orly Yariv,Orly Yariv,Idit Peretz,Ofer Rotem,Elizabeth Dudnik,Elizabeth Dudnik,Alona Zer,Alona Zer,Aaron M. Allen,Aaron M. Allen +12 more
TL;DR: In this paper, the authors report their experience with durvalumab after high-dose radiotherapy in stage III non-small cell lung cancer (NSCLC) patients.
Journal ArticleDOI
Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial.
Andreas Hallqvist,Stefan Bergström,Hedvig Björkestrand,Anna-Maja Svärd,Simon Ekman,Erik Lundin,Erik Holmberg,Mikael Johansson,Signe Friesland,Jan Nyman +9 more
TL;DR: Dose-escalated concurrent chemoradiotherapy to 84 Gy to primary tumor and nodal disease is hazardous, with a high risk of excessive toxicity, whereas modern standard dose chemoradaotherapy with proper staging given in the control arm shows a promising outcome with a median survival of 45 months and a 3-year survival of 56% (NCT01664663).
Journal ArticleDOI
The cardiac toxicity of radiotherapy - a review of characteristics, mechanisms, diagnosis, and prevention.
Tianhui Wei,Yufeng Cheng +1 more
TL;DR: In this article, the authors reviewed recent researches about cardiac toxicity of radiotherapy in clinical characteristics, mechanisms, diagnosis, and prevention, and concluded that early diagnosis and interventions for the prevention of RIHD are crucial.
Journal ArticleDOI
Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?
TL;DR: In this article, the authors present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for locally-advanced non-small cell lung cancer (LA-NSCLC).
References
More filters
Journal ArticleDOI
Cancer statistics, 2016
TL;DR: Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.
Journal Article
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
TL;DR: The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.
Journal ArticleDOI
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley,Rebecca Paulus,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Chen Hu,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Yolanda I. Garces,Samir Narayan,Puneeth Iyengar,Cliff G. Robinson,Raymond B. Wynn,Christopher Koprowski,Joanne Meng,Jonathan J. Beitler,Rakesh Gaur,Walter J. Curran,Hak Choy +21 more
TL;DR: Overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer was compared.
Journal ArticleDOI
Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung Cancer
Kiyoyuki Furuse,Masahiro Fukuoka,Masaaki Kawahara,Hideki Nishikawa,Y. Takada,Shinzoh Kudoh,Nobuyuki Katagami,Yutaka Ariyoshi +7 more
TL;DR: In selected patients with unresectable stage III NSCLC, the concurrent approach yields a significantly increased response rate and enhanced median survival duration when compared with the sequential approach.
Journal ArticleDOI
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
Robert O. Dillman,Stephen L. Seagren,Kathleen J. Propert,Julio Guerra,Walter L. Eaton,Michael C. Perry,Robert W. Carey,Emil Frei,Mark R. Green +8 more
TL;DR: In patients with Stage III non-small-cell lung cancer, induction chemotherapy with cisplatin and vinblastine before radiation significantly improves median survival and doubles the number of long-term survivors, as compared with radiation therapy alone.
Related Papers (3)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley,Rebecca Paulus,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Chen Hu,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Yolanda I. Garces,Samir Narayan,Puneeth Iyengar,Cliff G. Robinson,Raymond B. Wynn,Christopher Koprowski,Joanne Meng,Jonathan J. Beitler,Rakesh Gaur,Walter J. Curran,Hak Choy +21 more
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
Stephen G. Chun,Chen Hu,Hak Choy,R.U. Komaki,Robert Timmerman,Steven E. Schild,Jeffrey A. Bogart,Michael C. Dobelbower,Walter Bosch,James M. Galvin,V.S. Kavadi,Samir Narayan,Puneeth Iyengar,Clifford G. Robinson,Raymond B. Wynn,Adam Raben,Mark E. Augspurger,Robert MacRae,Rebecca Paulus,Jeffrey D. Bradley +19 more
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Auperin,Cécile Le Péchoux,Estelle Rolland,Walter J. Curran,Kiyoyuki Furuse,Pierre Fournel,José Belderbos,Gerald H. Clamon,Hakki Cuneyt Ulutin,Rebecca Paulus,Takeharu Yamanaka,Marie-Cecile Bozonnat,Apollonia L.J. Uitterhoeve,Xiaofei Wang,Lesley A. Stewart,Rodrigo Arriagada,Sarah Burdett,Jean-Pierre Pignon +17 more